首页> 外文期刊>Consultant. >Treatment of Severe ACE Inhibitor Angioedema: Current and Future Therapies
【24h】

Treatment of Severe ACE Inhibitor Angioedema: Current and Future Therapies

机译:严重ACE抑制剂血管性水肿的治疗:当前和未来的治疗方法。

获取原文
获取原文并翻译 | 示例
           

摘要

For many years, corticosteroids. antihistamines, and epinephrine have been used to treat severe angioedema related to therapy with angiotensin-converting enzyme inhibitors (ACEIs). However, no clear evidence exists to support these therapies in patients who present with ACEI-induced angioedema. Moreover, no clear guidelines are practiced or applied in U.S. hospitals, in contrast with a number of European countries. Despite that the newer medications ecallantide and icatibant have demonstrated efficacy in treating hereditary angioedema. few recent randomized clinical trials have been published investigating the benefits of these agents in treating ACEI angioedema. This literature review summarizes the most recent studies and evidence in the approach to ACEI angioedema treatment for primary care providers.
机译:多年来,皮质类固醇。抗组胺药和肾上腺素已用于治疗与血管紧张素转换酶抑制剂(ACEIs)治疗相关的严重血管性水肿。但是,尚无明确证据支持患有ACEI诱导的血管性水肿的患者接受这些疗法。此外,与许多欧洲国家相比,美国医院没有实践或应用明确的指南。尽管有新药ecallantide和icatibant已显示出治疗遗传性血管性水肿的功效。最近很少有关于研究这些药物在治疗ACEI血管性水肿中的益处的随机临床试验发表。这篇文献综述总结了针对初级保健提供者的ACEI血管性水肿治疗方法的最新研究和证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号